Organon (OGN) Total Non-Current Liabilities (2020 - 2026)

Organon (OGN) posted quarterly Total Non-Current Liabilities of $11.1 billion for Q1 2026, down 4.4% year-over-year from $11.6 billion in Q1 2025, and little changed on a QoQ basis from $11.1 billion in Q4 2025.

Organon (OGN) Total Non-Current Liabilities (2020 - 2026) Analysis & Trends

Organon (OGN) has reported Total Non-Current Liabilities for 7 consecutive years, with $11.1 billion the latest figure, recorded in Q1 2026.

  • In Q1 2026, Total Non-Current Liabilities fell 4.4% year-over-year to $11.1 billion; the TTM figure through Mar 2026 stood at $11.1 billion (down 4.4% YoY), while the FY2025 annual figure was $11.1 billion, down 4.68% from the prior year.
  • Total Non-Current Liabilities came in at $11.1 billion for Q1 2026 at Organon, roughly flat from $11.1 billion in the prior quarter.
  • The five-year high for Total Non-Current Liabilities was $11.7 billion in Q4 2023, with the low at $11.1 billion in Q3 2022.
  • Average Total Non-Current Liabilities over 5 years is $11.4 billion, with a median of $11.4 billion recorded in 2022.
  • The largest YoY upside for Total Non-Current Liabilities was 270.75% in 2022 against a maximum downside of 11.13% in 2022.
  • Year by year, Total Non-Current Liabilities stood at $11.4 billion in 2022, then gained by 2.45% to $11.7 billion in 2023, then dropped by 0.55% to $11.7 billion in 2024, then slipped by 4.68% to $11.1 billion in 2025, then rose by 0.02% to $11.1 billion in 2026.
  • According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $11.1 billion, $11.1 billion, and $11.5 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Eli Lilly 1,066.16 Bn 1,060.88 Bn 16.22 Bn 48.74 Bn
2 Johnson & Johnson 611.69 Bn 589.64 Bn 15.96 Bn 119.22 Bn
3 AbbVie 444.34 Bn 434.99 Bn 10.78 Bn 109.01 Bn
4 Astrazeneca 284.94 Bn 277.05 Bn 12.61 Bn -34.06 Bn
5 Merck 224.23 Bn 218.58 Bn 12.09 Bn 75.17 Bn
6 Amgen 195.12 Bn 183.08 Bn 5.87 Bn 80.55 Bn
7 Gilead Sciences 156.45 Bn 148.73 Bn 5.52 Bn 31.56 Bn
8 Pfizer 136.01 Bn 123.24 Bn -1.21 Bn 113.51 Bn
9 Novartis Ag 113.45 Bn 113.67 Bn - 100.00 Mn
10 Organon 3.53 Bn 2.41 Bn 783.00 Mn 11.11 Bn

Historic Data

Download Data
DateValue
Mar 31, 2026 11.11 Bn
Dec 31, 2025 11.11 Bn
Sep 30, 2025 11.52 Bn
Jun 30, 2025 11.65 Bn
Mar 31, 2025 11.62 Bn
Dec 31, 2024 11.65 Bn
Sep 30, 2024 11.59 Bn
Jun 30, 2024 11.46 Bn
Mar 31, 2024 11.29 Bn
Dec 31, 2023 11.72 Bn
Sep 30, 2023 11.18 Bn
Jun 30, 2023 11.14 Bn
Mar 31, 2023 11.08 Bn
Dec 31, 2022 11.44 Bn
Sep 30, 2022 11.06 Bn
Jun 30, 2022 11.30 Bn
Mar 31, 2022 11.39 Bn
Dec 31, 2021 11.73 Bn
Sep 30, 2021 12.45 Bn
Jun 30, 2021 12.36 Bn